Abstract
1) The MICs (106) of BMY-28100, cefaclor (CCL), and cephalexin (CEX) were determined against 55 strains of Staphylococcus aureus isolated from the lesions of skin infections. The MICs were in the order BMY-28100<CCL<CEX. The rates of resistant strains (MIC>12.5μg/ml) were 29.1% for BMY-28100, 36.4% for CCL and 60.0% for CEX.
2) Serum and skin levels of BMY-28100 were followed in 5 rats, 0.5, 1, 2 and 4h after oral administration of BMY-28100 (20mg/kg in terms of BMY-28100). Serum levels were 2.0, 6.2, 7.0 and 4.1μg/ml and the corresponding skin levels were 0.9, 2.6, 3.6 and 2.5μg/g.
3) BMY-28100 was used clinically in 13 cases of skin infection and the following results were obtained: excellent 8, good 1 and fair 4 cases. No side effects or abnormal laboratory findings attributable to the drug were observed.
